help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by TAYLOR, D. A.
Right arrow Articles by O'CONNOR, B. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by TAYLOR, D. A.
Right arrow Articles by O'CONNOR, B. J.

Am. J. Respir. Crit. Care Med., Volume 160, Number 1, July 1999, 237-243

A Dose-dependent Effect of the Novel Inhaled Corticosteroid Ciclesonide on Airway Responsiveness to Adenosine-5'-Monophosphate in Asthmatic Patients

DAVID A. TAYLOR, MARIANNE W. JENSEN, VARSHA KANABAR, RENATE ENGELSTÄTTER, VOLKER W. STEINIJANS, PETER J. BARNES, and BRIAN J. O'CONNOR

Royal Brompton Clinical Studies Unit, Department of Thoracic Medicine, National Heart and Lung Institute at Imperial College School of Medicine, London, United Kingdom; and Byk Gulden Pharmaceuticals, Konstanz, Germany

Inhaled corticosteroids decrease airway responsiveness in asthma partly through suppression of airway inflammation. We have previously demonstrated that inhaled budesonide reduced airway responsiveness to the mast cell stimulus adenosine-5'-monophosphate (AMP) to a threefold greater extent than to methacholine and sodium metabisulfite, suggesting that AMP responsiveness may be a more sensitive marker of airway inflammation and steroid action in order to assess a dose-response relationship. To investigate this, we studied the effects of three doses of the novel corticosteroid ciclesonide (50 µg, 200 µg, and 800 µg) inhaled as a dry powder twice daily on airway responsiveness to AMP and inflammatory parameters in induced sputum. In a three-parallel-dose group, double-blind, placebo-controlled, randomized, crossover study, with a washout period of 3 to 8 wk, a total of 29 patients with mild to moderate allergic asthma underwent AMP challenge and sputum induction before and after 14 d of treatment with ciclesonide or matched placebo. Compared with placebo, ciclesonide 100 µg, 400 µg, and 1,600 µg daily reduced airway responsiveness to AMP by 1.6 (95% confidence interval [CI], -0.1 to 3.4, not significant [NS]), 2.0 (95% CI, 0.4 to 3.6, p < 0.05), and 3.4 (95% CI, 2.3 to 4.4, p < 0.05) doubling doses, respectively, and this reduction in airway responsiveness was dose-dependent (p = 0.039). A significant reduction in the percentage of eosinophils in induced sputum was observed after 400 µg and 1,600 µg daily ciclesonide (p < 0.05), but this was not dose-dependent. Sputum eosinophil cationic protein (ECP) was significantly reduced after 400 µg daily ciclesonide only (p < 0.05). Thus, in patients with mild to moderate asthma, assessment of airway responsiveness to AMP, rather than inflammatory parameters in induced sputum, represents a sensitive method to evaluate a dose-response relationship of an inhaled corticosteroid and may have applications in evaluating other novel inhaled corticosteroids.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
J. Cohen, W. R. Douma, N. H. T. ten Hacken, J. M. Vonk, M. Oudkerk, and D. S. Postma
Ciclesonide improves measures of small airway involvement in asthma
Eur. Respir. J., June 1, 2008; 31(6): 1213 - 1220.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Duong, P. Subbarao, E. Adelroth, G. Obminski, T. Strinich, M. Inman, S. Pedersen, and P. M. O'Byrne
Sputum Eosinophils and the Response of Exercise-Induced Bronchoconstriction to Corticosteroid in Asthma
Chest, February 1, 2008; 133(2): 404 - 411.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
What role for {blacktriangledown}ciclesonide in asthma?
DTB, November 1, 2007; 45(11): 86 - 88.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
P. J. Barnes
Scientific rationale for using a single inhaler for asthma control
Eur. Respir. J., March 1, 2007; 29(3): 587 - 595.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. Cerasoli Jr
Developing the Ideal Inhaled Corticosteroid
Chest, July 1, 2006; 130(1_suppl): 54S - 64S.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. Bateman, J. Karpel, T. Casale, S. Wenzel, and D. Banerji
Ciclesonide Reduces the Need for Oral Steroid Use in Adult Patients With Severe, Persistent Asthma
Chest, May 1, 2006; 129(5): 1176 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
S. Szefler, S. Rohatagi, J. Williams, M. Lloyd, S. Kundu, and D. Banerji
Ciclesonide, a Novel Inhaled Steroid, Does Not Affect Hypothalamic-Pituitary-Adrenal Axis Function in Patients With Moderate-to-Severe Persistent Asthma
Chest, September 1, 2005; 128(3): 1104 - 1114.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. G. Belvisi, D. S. Bundschuh, M. Stoeck, S. Wicks, S. Underwood, C. H. Battram, E.-B. Haddad, S. E. Webber, and M. L. Foster
Preclinical Profile of Ciclesonide, a Novel Corticosteroid for the Treatment of Asthma
J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 568 - 574.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
K. Richter, F. Kanniess, C. Biberger, R. Nave, and H. Magnussen
Comparison of the Oropharyngeal Deposition of Inhaled Ciclesonide and Fluticasone Propionate in Patients With Asthma
J. Clin. Pharmacol., February 1, 2005; 45(2): 146 - 152.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. Foresi, B. Mastropasqua, A. Chetta, R. D'Ippolito, R. Testi, D. Olivieri, and A. Pelucchi
Step-Down Compared to Fixed-Dose Treatment With Inhaled Fluticasone Propionate in Asthma
Chest, January 1, 2005; 127(1): 117 - 124.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. Proietti, A. Di Maria, and R. Polosa
Monitoring the Adjustment of Antiasthma Medications With Adenosine Monophosphate Bronchoprovocation
Chest, October 1, 2004; 126(4): 1384 - 1385.
[Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. C. Grootendorst and K. F. Rabe
Mechanisms of Bronchial Hyperreactivity in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, April 1, 2004; 1(2): 77 - 87.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
K Phillips, J Oborne, T W Harrison, and A E Tattersfield
Use of sequential quadrupling dose regimens to study efficacy of inhaled corticosteroids in asthma
Thorax, January 1, 2004; 59(1): 21 - 25.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
S. Rohatagi, S. Appajosyula, H. Derendorf, S. Szefler, R. Nave, K. Zech, and D. Banerji
Risk-Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/Pharmacodynamic Perspective
J. Clin. Pharmacol., January 1, 2004; 44(1): 37 - 47.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
L. Prieto, L. Bruno, V. Gutierrez, S. Uixera, C. Perez-Frances, A. Lanuza, and A. Ferrer
Airway Responsiveness to Adenosine 5'-Monophosphate and Exhaled Nitric Oxide Measurements: Predictive Value as Markers for Reducing the Dose of Inhaled Corticosteroids in Asthmatic Subjects
Chest, October 1, 2003; 124(4): 1325 - 1333.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
G.F. Joos and B. O'Connor
Indirect airway challenges
Eur. Respir. J., June 1, 2003; 21(6): 1050 - 1068.
[Abstract] [Full Text] [PDF]

Home page
 QJMHome page
G.P. Currie, C.M. Jackson, S.A. Ogston, and B.J. Lipworth
Airway-stabilizing effect of long-acting {beta}2-agonists as add-on therapy to inhaled corticosteroids
QJM, June 1, 2003; 96(6): 435 - 440.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
N.J. Vanacker, E. Palmans, R.A. Pauwels, and J.C. Kips
Dose-related effect of inhaled fluticasone on allergen-induced airway changes in rats
Eur. Respir. J., October 1, 2002; 20(4): 873 - 879.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S.L. Jones, P. Herbison, J.O. Cowan, E.M. Flannery, R.J. Hancox, C.R. McLachlan, and D.R. Taylor
Exhaled NO and assessment of anti-inflammatory effects of inhaled steroid: dose-response relationship
Eur. Respir. J., September 1, 2002; 20(3): 601 - 608.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. P. Currie and B. J. Lipworth
Bronchoprotective Effects of Leukotriene Receptor Antagonists in Asthma* : A Meta-analysis
Chest, July 1, 2002; 122(1): 146 - 150.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R Polosa, S Rorke, and S T Holgate
Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease
Thorax, July 1, 2002; 57(7): 649 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
Leader of the Working Group:, J.C. Kips, Members of the Working Group:, M.D. Inman, L. Jayaram, E.H. Bel, K. Parameswaran, M.M.M. Pizzichini, I.D. Pavord, R. Djukanovic, et al.
The use of induced sputum in clinical trials
Eur. Respir. J., July 1, 2002; 20(37_suppl): 47S - 50s.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Weinbrenner, D. Huneke, M. Zschiesche, G. Engel, W. Timmer, V. W. Steinijans, T. Bethke, W. Wurst, A. Drollmann, H. J. Kaatz, et al.
Circadian Rhythm of Serum Cortisol after Repeated Inhalation of the New Topical Steroid Ciclesonide
J. Clin. Endocrinol. Metab., May 1, 2002; 87(5): 2160 - 2163.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. C. AHRENS, M. E. TERESI, S.-H. HAN, D. DONNELL, J. A. VANDEN BURGT, and C. R. LUX
Asthma Stability after Oral Prednisone . A Clinical Model for Comparing Inhaled Steroid Potency
Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1138 - 1145.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K.F. Rabe and D.T. Schmidt
Pharmacological treatment of asthma today
Eur. Respir. J., July 2, 2001; 18(34_suppl): 34S - 40s.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
D.S. Postma, C. Sevette, Y. Martinat, N. Schlosser, J. Aumann, and H. Kafe
Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening
Eur. Respir. J., June 1, 2001; 17(6): 1083 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. E. Silkoff, P. McClean, M. Spino, L. Erlich, A. S. Slutsky, and N. Zamel
Dose-Response Relationship and Reproducibility of the Fall in Exhaled Nitric Oxide After Inhaled Beclomethasone Dipropionate Therapy in Asthma Patients
Chest, May 1, 2001; 119(5): 1322 - 1328.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G De Meer, D J J Heederik, B Brunekreef, and D S Postma
Repeatability of bronchial hyperresponsiveness to adenosine-5'-monophosphate (AMP) by a short dosimeter protocol
Thorax, May 1, 2001; 56(5): 362 - 365.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. M. WILSON, L. C. ORR, E. J. SIMS, O. J. DEMPSEY, and B. J. LIPWORTH
Antiasthmatic Effects of Mediator Blockade versus Topical Corticosteroids in Allergic Rhinitis and Asthma
Am. J. Respir. Crit. Care Med., October 1, 2000; 162(4): 1297 - 1301.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
L. M. van den TOORN, J.-B. PRINS, S. E. OVERBEEK, H. C. HOOGSTEDEN, and J. C. de JONGSTE
Adolescents in Clinical Remission of Atopic Asthma Have Elevated Exhaled Nitric Oxide Levels and Bronchial Hyperresponsiveness
Am. J. Respir. Crit. Care Med., September 1, 2000; 162(3): 953 - 957.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society